Cargando…

Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System

Coronavirus disease 2019 (COVID-19), a respiratory illness caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has claimed over one million lives worldwide since December 2019. The complement system, while a first-line immune defense against invading pathogens, has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barkoff, Courtney M., Mousa, Shaker A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823480/ https://www.ncbi.nlm.nih.gov/pubmed/33374356 http://dx.doi.org/10.3390/biomedicines9010011

Ejemplares similares

The Rationale for Potential Pharmacotherapy of COVID-19
por: Saber-Ayad, Maha, et al.
Publicado: (2020)

Behavioral Intervention versus Pharmacotherapy or Their Combinations in the Management of Overactive Bladder Dysfunction
por: Tran, Khanh, et al.
Publicado: (2009)

Management of Pancreatic Cancer and Its Microenvironment: Potential Impact of Nano-Targeting
por: Perko, Nardeen, et al.
Publicado: (2022)

Cognitive behavioral treatment for narcolepsy: can it complement pharmacotherapy?
por: Marín Agudelo, Hernán Andrés, et al.
Publicado: (2014)

Towards Novel Potential Molecular Targets for Antidepressant and Antipsychotic Pharmacotherapies
por: Kositsyn, Yuriy M., et al.
Publicado: (2023)

Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
por: Vecera, Courtney M., et al.
Publicado: (2023)

Rationale for targeting complement in COVID‐19
por: Polycarpou, Anastasia, et al.
Publicado: (2020)

Noninvasive Cerebellar Stimulation as a Complement Tool to Pharmacotherapy
por: Ferrucci, Roberta, et al.
Publicado: (2019)

Experimental Pharmacotherapy for COVID-19: The Latest Advances
por: Pagliano, Pasquale, et al.
Publicado: (2021)

Saudi Heart Rhythm Society Task Force on Management of Potential Arrhythmogenicity Associated with Pharmacotherapy for COVID-19
por: AlShoaibi, Naeem A., et al.
Publicado: (2020)

Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies
por: Baburaj, Gayathri, et al.
Publicado: (2021)

Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective
por: Talasaz, Azita Hajhossein, et al.
Publicado: (2020)

The Complement System: A Potential Therapeutic Target in Liver Cancer
por: Yuan, Meng, et al.
Publicado: (2022)

Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease
por: Ng, Nicole, et al.
Publicado: (2021)

The use of nebulized pharmacotherapies during the COVID-19 pandemic
por: Sethi, Sanjay, et al.
Publicado: (2020)

Emerging pharmacotherapies for COVID-19
por: Salvi, Rachana, et al.
Publicado: (2020)

Pharmacotherapy Based on ACE2 Targeting and COVID-19 Infection
por: Vitiello, Antonio, et al.
Publicado: (2022)

Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety
por: Téllez Arévalo, Angélica María, et al.
Publicado: (2022)

Hepatitis C virus management: potential impact of nanotechnology
por: Elberry, Mostafa H., et al.
Publicado: (2017)

Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies
por: Faour, Wissam H., et al.
Publicado: (2021)

Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS
por: Amini, Shahideh, et al.
Publicado: (2022)

Pharmacotherapy of Insomnia
por: Neubauer, David N, et al.
Publicado: (2018)

Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic
por: Carron, Jennifer, et al.
Publicado: (2020)

Targeting complement cascade: an alternative strategy for COVID-19
por: Ram Kumar Pandian, Sureshbabu, et al.
Publicado: (2020)

DGI recommendations for COVID-19 pharmacotherapy
por: Malin, Jakob J., et al.
Publicado: (2020)

Antiglaucoma pharmacotherapy
por: Tătaru, CP, et al.
Publicado: (2012)

Current Pharmacotherapy and Multi-Target Approaches for Alzheimer’s Disease
por: Cheong, Siew Lee, et al.
Publicado: (2022)

Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain
por: Bernatoniene, Jurga, et al.
Publicado: (2023)

Pharmacotherapies for COPD
por: Ejiofor, Stan, et al.
Publicado: (2013)

Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future
por: Hertanto, Decsa Medika, et al.
Publicado: (2021)

Complement as a target in COVID-19?
por: Risitano, Antonio M., et al.
Publicado: (2020)

The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies
por: Querol, Luis A., et al.
Publicado: (2022)

Impact of Pharmacotherapy on Insomnia in Patients with Alzheimer’s Disease
por: Roland, Joshua P., et al.
Publicado: (2021)

Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions
por: Vitiello, Antonio, et al.
Publicado: (2022)

The incretin/glucagon system as a target for pharmacotherapy of obesity
por: Del Prato, Stefano, et al.
Publicado: (2021)

Pharmacotherapy as an adjunct to vitrectomy
por: Villegas, Victor M., et al.
Publicado: (2021)

Fragile X targeted pharmacotherapy: lessons learned and future directions
por: Erickson, Craig A., et al.
Publicado: (2017)

Diagnostic Approaches for COVID-19 and Its Associated Complications
por: Wang, Ivan E., et al.
Publicado: (2021)

Targeting complement activation in COVID-19
por: Kulkarni, Hrishikesh S., et al.
Publicado: (2020)

Potential pharmacotherapy for Zinner syndrome
por: Takeshima, Teppei
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lmj41egtodpoec7q248un9o6tb